BRIAN PILCHER, PHD APPOINTED AS CHIEF SCIENTIFIC OFFICER AT SUNEVA MEDICAL

March 28, 2019 (San Diego) — Suneva® Medical, Inc., privately held aesthetics company, announces the appointment of Chief Science Officer, Brian Pilcher PhD.

Dr. Brian K. Pilcher joins Suneva Medical with over 18 years of experience in Dermatology and Aesthetics, most recently as Principal of Critical MASS Scientific Strategy Consultants, where he worked to develop programs in support of established product life cycle and new product launches, as well as medical affairs and clinical education activities. He also served as Vice President of Medical Affairs for Merz North America, Vice President of Medical Affairs and Clinical Education for BioForm Medical, and Director of Research for Cutanix Corporation. 

In each of these roles, Dr. Pilcher has leveraged his unique combination of scientific and commercial expertise to direct and implement innovative and effective medical and clinical communications platforms and lead medical affairs teams in developing strong relationships with both thought leaders and the broader medical community. Leading a team of 40 nurse and physician assistant educators whose goal was to ensure optimal clinical results, Dr. Pilcher has developed novel educational initiatives to ensure safe and effective uses of drugs and medical devices, while focusing on the highest standards of patient safety and satisfaction. 

Dr. Pilcher earned his PhD in Anatomy and Cell Biology from the University Of Oklahoma College Of Medicine. He completed his post-graduate training in Dermatology at Washington University in St. Louis and served as an Assistant Professor at University of Texas Southwestern Medical Center in the Department of Cell Biology where his research focus was on the cellular and molecular mechanisms of wound repair.

“I am honored and excited to join the Suneva Medical team as we enter into the company’s next phase of becoming a leader in regenerative aesthetics,” said Pilcher. “I am confident that by building a strong scientific and clinical platform we will take the brand and new and current portfolio of products to the next level.”

About Suneva Medical, Inc.
Suneva Medical is a privately‐held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years old. The company markets Bellafill® in the U.S., Canada, Hong Kong, Korea and Mexico. For more information, visit www.sunevamedical.com

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.